ACE Inhibitors News and Research

RSS
ACE inhibitors act to reduce hypertension by interfering with the conversion of angiotensin I to artery-constricting angiotensin II. Blocking the production of angiotensin II results in arterial vasodilation and an accompanying reduction in blood pressure. ACE inhibitors currently are recommended as first-line therapy for hypertension in certain patient populations, because of their safety and efficacy.
Beta blockers offer no additional benefit for heart attack patients who take other drugs

Beta blockers offer no additional benefit for heart attack patients who take other drugs

VUMC and Bayer agree on strategic research alliance to develop new therapies for kidney diseases

VUMC and Bayer agree on strategic research alliance to develop new therapies for kidney diseases

Drug combination improves outcomes in patients with stable coronary or peripheral artery disease

Drug combination improves outcomes in patients with stable coronary or peripheral artery disease

Drug combination superior in preventing further heart complications in people with vascular disease

Drug combination superior in preventing further heart complications in people with vascular disease

Benefit of ICDs may be uncertain with cumulative use of effective medications, study shows

Benefit of ICDs may be uncertain with cumulative use of effective medications, study shows

Research shows SBRT as viable curative option for older lung cancer patients

Research shows SBRT as viable curative option for older lung cancer patients

Lack of exercise, excessive weight linked to heart failure that has poor prognosis

Lack of exercise, excessive weight linked to heart failure that has poor prognosis

Study shows heart medications prevent cardiovascular damage during breast cancer treatment

Study shows heart medications prevent cardiovascular damage during breast cancer treatment

ESC releases novel position paper on tackling cardiotoxicity of anticancer treatments

ESC releases novel position paper on tackling cardiotoxicity of anticancer treatments

Lisinopril oral solution approved for treatment of hypertension in children and adults

Lisinopril oral solution approved for treatment of hypertension in children and adults

Study shows drugs for hypertension may help treat mood disorders

Study shows drugs for hypertension may help treat mood disorders

Pharmacotherapy reduces conduction system disease risk

Pharmacotherapy reduces conduction system disease risk

Overcoming barriers to move beyond race-based treatment decisions

Overcoming barriers to move beyond race-based treatment decisions

CKD status does not affect health status outcomes after AMI

CKD status does not affect health status outcomes after AMI

Aliskiren fails to show benefit for heart failure patients with diabetes

Aliskiren fails to show benefit for heart failure patients with diabetes

Tackling insulin resistance may reduce recurrence after stroke

Tackling insulin resistance may reduce recurrence after stroke

Case Western scientist to lead a pair of studies to develop more effective treatment for CF

Case Western scientist to lead a pair of studies to develop more effective treatment for CF

Paying close attention to results of simple blood test can help predict risk of kidney failure, death

Paying close attention to results of simple blood test can help predict risk of kidney failure, death

Study reveals poor levels of use, availability and affordability of cardiovascular disease medicines worldwide

Study reveals poor levels of use, availability and affordability of cardiovascular disease medicines worldwide

Radical shift required in use of heart medicine worldwide

Radical shift required in use of heart medicine worldwide

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.